World's Best Scientists 2026 revealed!
Award Badge
Immunology
Spain
2025
Award Badge
Medicine
Spain
2023

D-Index & Metrics

Immunology

D-Index
109
Citations
47378
World Ranking
515
National Ranking
46

Medicine

D-Index
109
Citations
47459
World Ranking
5744
National Ranking
563

Ignacio Melero publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Ignacio Melero sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 402 publications — 81st percentile

81% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Ignacio Melero D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Ignacio Melero sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 109 D-Index — 90th percentile

90% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Research.com Recognitions

  • 2025 - Research.com Immunology in Spain Leader Award
  • 2023 - Research.com Medicine in Spain Leader Award
  • 2022 - Research.com Immunology in Spain Leader Award

Overview

Ignacio Melero is affiliated with the University of Navarra in Spain and has a significant focus on cancer immunotherapy and related biomedical research. Their primary fields of study include Medicine and Immunology and Microbiology, with subfields concentrating on Oncology, Immunology, Molecular Biology, Radiology, Nuclear Medicine and Imaging, and Hepatology.

The scientist's research topics cover a range of areas within cancer and immune system interactions. The main topics associated with their work include:

  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • Immune Cell Function and Interaction
  • Monoclonal and Polyclonal Antibodies Research
  • Immune cells in cancer
  • Hepatocellular Carcinoma Treatment and Prognosis

Ignacio Melero has published extensively in various peer-reviewed journals and venues. Frequent publication outlets for their work include:

  • Annals of Oncology (28 publications)
  • Journal for ImmunoTherapy of Cancer (21 publications)
  • Regular and Young Investigator Award Abstracts (21 publications)
  • Journal of Clinical Oncology (19 publications)
  • Cancer Research (18 publications)

Their recent scientific papers reflect a concentration on immunotherapy approaches, particularly in liver cancer and tumor immunology. Notable recent publications include:

  • "Advances in immunotherapy for hepatocellular carcinoma" (2021, Nature Reviews Gastroenterology & Hepatology)
  • "Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib" (2020, JAMA Oncology)
  • "Cancer vaccines: the next immunotherapy frontier" (2022, Nature Cancer)
  • "CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity" (2020, Immunity)
  • "Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors" (2020, Nature Medicine)

Collaboration has been an important aspect of their research, with several frequent coauthors, indicating sustained joint work in the field. These coauthors include:

  • Pedro Berraondo
  • Álvaro Teijeira
  • Miguel F. Sanmamed
  • María E. Rodriguez-Ruiz
  • Maite Álvarez

Best Publications

  • Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

    Anthony B. El-Khoueiry;Bruno Sangro;Thomas Yau;Todd S. Crocenzi

  • Dendritic cells in cancer immunology and immunotherapy.

    Stefanie K Wculek;Francisco J Cueto;Adriana M Mujal;Ignacio Melero

  • Advances in immunotherapy for hepatocellular carcinoma

    Bruno Sangro;Pablo Sarobe;Sandra Hervás-Stubbs;Ignacio Melero

  • Cytokines in clinical cancer immunotherapy

    Pedro Berraondo;Miguel F. Sanmamed;María C Ochoa;Iñaki Etxeberria

  • Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.

    Thomas Yau;Yoon Koo Kang;Tae You Kim;Anthony B. El-Khoueiry

  • A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.

    Bruno Sangro;Carlos Gomez-Martin;Manuel de la Mata;Mercedes Iñarrairaegui

  • Therapeutic vaccines for cancer: an overview of clinical trials

    Ignacio Melero;Gustav Gaudernack;Winald Gerritsen;Christoph Huber

  • Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3

    Jun Wang;Miguel F. Sanmamed;Ila Datar;Tina Tianjiao Su

  • Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer

    Scott Gettinger;Jungmin Choi;Katherine Hastings;Anna Truini

  • Evolving synergistic combinations of targeted immunotherapies to combat cancer.

    Ignacio Melero;David M. Berman;M. Angela Aznar;Alan J. Korman

  • CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity.

    Álvaro Teijeira;Saray Garasa;María Gato;Carlos Alfaro

  • Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes.

    Deborah B. Doroshow;Miguel F. Sanmamed;Katherine Hastings;Katerina Politi

  • Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma.

    Kurt A. Schalper;Maria E. Rodriguez-Ruiz;Ricardo Diez-Valle;Alvaro López-Janeiro

  • Direct Effects of Type I Interferons on Cells of the Immune System

    Sandra Hervas-Stubbs;Jose Luis Perez-Gracia;Ana Rouzaut;Miguel Fernandez de Sanmamed

  • Phase I Trial of Intratumoral Injection of an Adenovirus Encoding Interleukin-12 for Advanced Digestive Tumors

    Bruno Sangro;Guillermo Mazzolini;Juan Ruiz;Maite Herraiz

  • Classification of current anticancer immunotherapies

    Lorenzo Galluzzi;Erika Vacchelli;José Manuel Bravo-San Pedro;Aitziber Buqué

  • Immunological landscape and immunotherapy of hepatocellular carcinoma

    Jesús Prieto;Ignacio Melero;Bruno Sangro

  • Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors.

    Kurt A. Schalper;Michael Carleton;Ming Zhou;Tian Chen

  • Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti–PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells

    Alfonso R. Sánchez-Paulete;Francisco J. Cueto;María Martínez-López;Sara Labiano

  • Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies

    Cariad Chester;Miguel F. Sanmamed;Jun Wang;Ignacio Melero

  • T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy.

    Ignacio Melero;Ana Rouzaut;Greg T. Motz;George Coukos

Frequent Co-Authors

Jesús Prieto
Jesús Prieto University of Navarra
Bruno Sangro
Bruno Sangro University of Navarra
Sandra Hervas-Stubbs
Sandra Hervas-Stubbs University of Navarra
Masatoshi Kudo
Masatoshi Kudo Kindai University
Lieping Chen
Lieping Chen Yale University
Kurt A. Schalper
Kurt A. Schalper Yale University
Winnie Yeo
Winnie Yeo Chinese University of Hong Kong
Tim Meyer
Tim Meyer University College London
Paolo A. Ascierto
Paolo A. Ascierto National Institutes of Health
Juan José Lasarte
Juan José Lasarte University of Navarra

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Immunology in the USA opens doors to various advanced nursing and healthcare roles, many of which can be pursued through specialized online degrees. For example, nurses interested in mental health can explore some of the most affordable pmhnp programs that combine immunological knowledge with psychiatric care. These programs offer a cost-effective route to becoming a Psychiatric-Mental Health Nurse Practitioner.

For those aiming at higher earnings, understanding the highest paid dnp specialties can guide your career planning. Specializing within these fields often requires additional credentials or bridge programs, such as transitioning from family nursing to more acute care settings.

If you are a Family Nurse Practitioner (FNP) looking to advance, consider an fnp to acute care np bridge program. This pathway allows you to expand your expertise to handle critically ill patients, integrating immunological principles necessary in acute care environments.

Alternatively, accelerated fnp program options are available online for those seeking to fast-track their career growth. These accelerated paths allow immunology-focused practitioners to gain credentials quicker, making it easier to transition into advanced practice roles.

Best Scientists Citing Ignacio Melero

Trending Scientists

Recently Published Articles